Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Agilent Technologies Inc (A) vs State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) Price & Performance

Agilent Technologies Inc
State Street SPDR Bloomberg 1-3 Month T-Bill ETF

Price performance

Price movement over the last 24 hours

Key statistics

Agilent Technologies Inc vs State Street SPDR Bloomberg 1-3 Month T-Bill ETF — how do they compare? Agilent Technologies Inc trades at $128.38 (market cap $37.04B), while State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.46. The key difference: Agilent Technologies Inc pays a 0.78% dividend while State Street SPDR Bloomberg 1-3 Month T-Bill ETF pays none. Which is the better fit depends on your goals.

ABIL
Market Cap
$37.04B
Sector
HealthFixed Income
52-Week High
$157.20$91.77
52-Week Low
$110.24$91.27
Enterprise Value
$38.59B
Dividend Yield
0.78%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Agilent Technologies Inc

Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.

The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.

State Street SPDR Bloomberg 1-3 Month T-Bill ETF

BIL trades at $91.43, down slightly by 0.01% over 24 hours, with a bearish technical outlook indicated by moving averages. The ETF maintains a consistent dividend payout of $0.27 per share, with recent distributions in H1-26 and upcoming in H2-26. Market sentiment is influenced by Federal Reserve rate hike speculation, as bond ETF inflows surge amid inflation concerns and stock volatility.

The outlook for BIL is cautious due to potential interest rate hikes in 2026, which could impact short-term Treasury yields. Risks include Fed policy uncertainty and macroeconomic shifts, but the ETF offers stability through regular dividends. Investors should weigh yield opportunities against interest rate sensitivity in the current environment.

Returns comparison

Trailing returns across standard periods

About Agilent Technologies Inc

Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.

Read more on A

About State Street SPDR Bloomberg 1-3 Month T-Bill ETF

BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.

Read more on BIL